Loading patent…
AssigneeGilead Biologics, Inc.
InventorsVictoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
Estimating the term…
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
A method of treating or inhibiting a fibrosis disease in a human in need thereof comprising, administering to the human an isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof specifically binds to human lysyl oxidase-like 2 (LOXL2) protein and comprises a heavy chain variable region complementarity determining regions (CDRs) comprising the amino acid sequences set forth as SEQ ID NOs:
A method of treating or inhibiting a fibrosis disease in a human in need thereof comprising, administering to the human an isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof specifically binds to human LOXL2 protein and comprises the heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NOs:
Dependencies are inferred from the claim text.